Literature DB >> 26868089

Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics.

Josep Julve1, Jesús M Martín-Campos2, Joan Carles Escolà-Gil3, Francisco Blanco-Vaca4.   

Abstract

The adequate absorption of lipids is essential for all mammalian species due to their inability to synthesize some essential fatty acids and fat-soluble vitamins. Chylomicrons (CMs) are large, triglyceride-rich lipoproteins that are produced in intestinal enterocytes in response to fat ingestion, which function to transport the ingested lipids to different tissues. In addition to the contribution of CMs to postprandial lipemia, their remnants, the degradation products following lipolysis by lipoprotein lipase, are linked to cardiovascular disease. In this review, we will focus on the structure-function and metabolism of CMs. Second, we will analyze the impact of gene defects reported to affect CM metabolism and, also, the role of CMs in other pathologies, such as atherothrombotic cardiovascular disease and diabetes mellitus. Third, we will provide an overview of the laboratory tests currently used to study CM disorders, and, finally, we will highlight current treatments in diseases affecting CMs.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abetalipoproteinemia; Atherosclerosis; Chylomicron; Chylomicron retention disease; Enterocyte; Hypobetalipoproteinemia; Laboratory testing; Therapy; Triglyceride; Type I hyperlipidemia; Type V hyperlipidemia

Mesh:

Substances:

Year:  2016        PMID: 26868089     DOI: 10.1016/j.cca.2016.02.004

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  16 in total

Review 1.  Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?

Authors:  Lynley M Doonan; Edward A Fisher; Jeffrey L Brodsky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-04-06       Impact factor: 4.698

Review 2.  Nuclear receptors, cholesterol homeostasis and the immune system.

Authors:  Sayyed Hamed Shahoei; Erik R Nelson
Journal:  J Steroid Biochem Mol Biol       Date:  2019-04-16       Impact factor: 4.292

3.  Metabolism of Triglyceride-Rich Lipoproteins.

Authors:  Jan Borén; Marja-Riitta Taskinen
Journal:  Handb Exp Pharmacol       Date:  2022

Review 4.  Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis.

Authors:  Bai-Hui Zhang; Fan Yin; Ya-Nan Qiao; Shou-Dong Guo
Journal:  Front Mol Biosci       Date:  2022-05-25

Review 5.  Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia.

Authors:  Jan Borén; Marja-Riitta Taskinen; Elias Björnson; Chris J Packard
Journal:  Nat Rev Cardiol       Date:  2022-03-22       Impact factor: 49.421

Review 6.  Lipoprotein-based drug delivery.

Authors:  Sara Busatto; Sierra A Walker; Whisper Grayson; Anthony Pham; Ming Tian; Nicole Nesto; Jacqueline Barklund; Joy Wolfram
Journal:  Adv Drug Deliv Rev       Date:  2020-08-11       Impact factor: 15.470

7.  The Contribution of Lipids to the Interindividual Response of Vitamin K Biomarkers to Vitamin K Supplementation.

Authors:  Jennifer M Kelly; Jose M Ordovas; Gregory Matuszek; Caren E Smith; Gordon S Huggins; Hassan S Dashti; Reiko Ichikawa; Sarah L Booth
Journal:  Mol Nutr Food Res       Date:  2019-10-03       Impact factor: 5.914

Review 8.  Role of the Enterocyte in Fructose-Induced Hypertriglyceridaemia.

Authors:  Simon Steenson; A Margot Umpleby; Julie A Lovegrove; Kim G Jackson; Barbara A Fielding
Journal:  Nutrients       Date:  2017-04-01       Impact factor: 5.717

Review 9.  Hypertriglyceridemia and atherosclerosis.

Authors:  Jia Peng; Fei Luo; Guiyun Ruan; Ran Peng; Xiangping Li
Journal:  Lipids Health Dis       Date:  2017-12-06       Impact factor: 3.876

Review 10.  Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.

Authors:  Oluwayemisi Esan; Anthony S Wierzbicki
Journal:  Drug Des Devel Ther       Date:  2020-07-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.